Payel Roy1, John Sidney2, Cecilia S Lindestam Arlehamn2, Elizabeth Phillips3,4, Simon Mallal5,4, Sujit Silas Armstrong Suthahar1, Monica Billitti1, Paul Rubiro2, Daniel Marrama2, Fabrizio Drago6, Jenifer Vallejo1, Vasantika Suryawanshi1, Marco Orecchioni1, Jeffrey Makings1, Paul J Kim7, Coleen A McNamara6, Bjoern Peters2,8, Alessandro Sette2,8, Klaus Ley1,9. 1. Center for Autoimmune Disease, Laboratory of Inflammation Biology (P.R., S.S.A.S., M.B., J.V., V.S., M.O., J.M., K.L.), La Jolla Institute for Immunology, CA. 2. Center for Infectious Disease and Vaccine Research (J.S., C.S.L.A., P.R., D.M., B.P., A.S.), La Jolla Institute for Immunology, CA. 3. Department of Medicine, Department of Pharmacology, Department of Pathology, Microbiology and Immunology (E.P.), Vanderbilt University Medical Center, Nashville, TN. 4. Institute for Immunology and Infectious Diseases, Murdoch University, Perth, WA (E.P., S.M.). 5. Department of Medicine (S.M.), Vanderbilt University Medical Center, Nashville, TN. 6. Cardiovascular Division, Department of Medicine, Cardiovascular Research Center, University of Virginia, Charlottesville (F.D., C.A.M.). 7. Division of Cardiovascular Medicine, Department of Medicine (P.J.K.), University of California, San Diego, La Jolla. 8. Department of Medicine (B.P., A.S.), University of California, San Diego, La Jolla. 9. Department of Bioengineering (K.L.), University of California, San Diego, La Jolla.
Abstract
BACKGROUND: CD (cluster of differentiation) 4+ T-cell responses to APOB (apolipoprotein B) are well characterized in atherosclerotic mice and detectable in humans. CD4+ T cells recognize antigenic peptides displayed on highly polymorphic HLA (human leukocyte antigen)-II. Immunogenicity of individual APOB peptides is largely unknown in humans. Only 1 HLA-II-restricted epitope was validated using the DRB1*07:01-APOB3036-3050 tetramer. We hypothesized that human APOB may contain discrete immunodominant CD4+ T-cell epitopes that trigger atherosclerosis-related autoimmune responses in donors with diverse HLA alleles. METHODS: We selected 20 APOB-derived peptides (APOB20) from an in silico screen and experimentally validated binding to the most commonly occurring human HLA-II alleles. We optimized a restimulation-based workflow to evaluate antigenicity of multiple candidate peptides in HLA-typed donors. This included activation-induced marker assay, intracellular cytokine staining, IFNγ (interferon gamma) enzyme-linked immunospot and cytometric bead array. High-throughput sequencing revealed TCR (T-cell receptor) clonalities of APOB-reactive CD4+ T cells. RESULTS: Using stringent positive, negative, and crossover stimulation controls, we confirmed specificity of expansion-based protocols to detect CD4+ T cytokine responses to the APOB20 pool. Ex vivo assessment of AIM+CD4+ T cells revealed a statistically significant autoimmune response to APOB20 but not to a ubiquitously expressed negative control protein, actin. Resolution of CD4+ T responses to the level of individual peptides using IFNγ enzyme-linked immunospot led to the discovery of 6 immunodominant epitopes (APOB6) that triggered robust CD4+ T activation in most donors. APOB6-specific responding CD4+ T cells were enriched in unique expanded TCR clonotypes and preferentially expressed memory markers. Cytometric bead array analysis detected APOB6-induced secretion of both proinflammatory and regulatory cytokines. In clinical samples from patients with angiographically verified coronary artery disease, APOB6 stimulation induced higher activation and memory phenotypes and augmented secretion of proinflammatory cytokines TNF (tumor necrosis factor) and IFNγ, compared with patients with low coronary artery disease. CONCLUSIONS: Using 3 cohorts, each with ≈20 donors, we discovered and validated 6 immunodominant, HLA-II-restricted APOB epitopes. The immune response to these APOB epitopes correlated with coronary artery disease severity.
BACKGROUND: CD (cluster of differentiation) 4+ T-cell responses to APOB (apolipoprotein B) are well characterized in atherosclerotic mice and detectable in humans. CD4+ T cells recognize antigenic peptides displayed on highly polymorphic HLA (human leukocyte antigen)-II. Immunogenicity of individual APOB peptides is largely unknown in humans. Only 1 HLA-II-restricted epitope was validated using the DRB1*07:01-APOB3036-3050 tetramer. We hypothesized that human APOB may contain discrete immunodominant CD4+ T-cell epitopes that trigger atherosclerosis-related autoimmune responses in donors with diverse HLA alleles. METHODS: We selected 20 APOB-derived peptides (APOB20) from an in silico screen and experimentally validated binding to the most commonly occurring human HLA-II alleles. We optimized a restimulation-based workflow to evaluate antigenicity of multiple candidate peptides in HLA-typed donors. This included activation-induced marker assay, intracellular cytokine staining, IFNγ (interferon gamma) enzyme-linked immunospot and cytometric bead array. High-throughput sequencing revealed TCR (T-cell receptor) clonalities of APOB-reactive CD4+ T cells. RESULTS: Using stringent positive, negative, and crossover stimulation controls, we confirmed specificity of expansion-based protocols to detect CD4+ T cytokine responses to the APOB20 pool. Ex vivo assessment of AIM+CD4+ T cells revealed a statistically significant autoimmune response to APOB20 but not to a ubiquitously expressed negative control protein, actin. Resolution of CD4+ T responses to the level of individual peptides using IFNγ enzyme-linked immunospot led to the discovery of 6 immunodominant epitopes (APOB6) that triggered robust CD4+ T activation in most donors. APOB6-specific responding CD4+ T cells were enriched in unique expanded TCR clonotypes and preferentially expressed memory markers. Cytometric bead array analysis detected APOB6-induced secretion of both proinflammatory and regulatory cytokines. In clinical samples from patients with angiographically verified coronary artery disease, APOB6 stimulation induced higher activation and memory phenotypes and augmented secretion of proinflammatory cytokines TNF (tumor necrosis factor) and IFNγ, compared with patients with low coronary artery disease. CONCLUSIONS: Using 3 cohorts, each with ≈20 donors, we discovered and validated 6 immunodominant, HLA-II-restricted APOB epitopes. The immune response to these APOB epitopes correlated with coronary artery disease severity.
Authors: Cecilia S Lindestam Arlehamn; John Pham; Roy N Alcalay; April Frazier; Evan Shorr; Chelsea Carpenter; John Sidney; Rekha Dhanwani; Julian Agin-Liebes; Francesca Garretti; Amy W Amara; David G Standaert; Elizabeth J Phillips; Simon A Mallal; Bjoern Peters; David Sulzer; Alessandro Sette Journal: J Immunol Date: 2019-05-13 Impact factor: 5.422
Authors: Deepali Malhotra; Jonathan L Linehan; Thamotharampillai Dileepan; You Jeong Lee; Whitney E Purtha; Jennifer V Lu; Ryan W Nelson; Brian T Fife; Harry T Orr; Mark S Anderson; Kristin A Hogquist; Marc K Jenkins Journal: Nat Immunol Date: 2016-01-04 Impact factor: 25.606
Authors: Melinda Y Hardy; Gautam Goel; Amy K Russell; Swee Lin G Chen Yi Mei; Gregor J E Brown; Suyue Wang; Evan Szymczak; Ruan Zhang; Kaela E Goldstein; Kristin M Neff; Leslie J Williams; Kenneth E Truitt; John L Dzuris; Jason A Tye-Din; Robert P Anderson Journal: Front Immunol Date: 2021-05-19 Impact factor: 7.561
Authors: Randi Vita; Swapnil Mahajan; James A Overton; Sandeep Kumar Dhanda; Sheridan Martini; Jason R Cantrell; Daniel K Wheeler; Alessandro Sette; Bjoern Peters Journal: Nucleic Acids Res Date: 2019-01-08 Impact factor: 16.971